YTH domain-containing family protein 3 (DF3)
1_MSATS 6_ VDQRP 11_ KGQGN 16_ KVSVQ 21_ NGSIH 26_ QKDAV 31_ NDDDF 36_ EPYLS 41_ SQTNQ 46_ SNSYP 51_ PMSDP 56_ YMPSY 61_ YAPSI 66_ GFPYS 71_ LGEAA 76_ WSTAG 81_ DQPMP 86_ YLTTY 91_ GQMSN 96_ GEHHY 101_ IPDGV 106_ FSQPG 111_ ALGNT 116_ PPFLG 121_ QHGFN 126_ FFPGN 131_ ADFST 136_ WGTSG 141_ SQGQS 146_ TQSSA 151_ YSSSY 156_ GYPPS 161_ SLGRA 166_ ITDGQ 171_ AGFGN 176_ DTLSK 181_ VPGIS 186_ SIEQG 191_ MTGLK 196_ IGGDL 201_ TAAVT 206_ KTVGT 211_ ALSSS 216_ GMTSI 221_ ATNSV 226_ PPVSS 231_ AAPKP 236_ TSWAA 241_ IARKP 246_ AKPQP 251_ KLKPK 256_ GNVGI 261_ GGSAV 266_ PPPPI 271_ KHNMN 276_ IGTWD 281_ EKGSV 286_ VKAPP 291_ TQPVL 296_ PPQTI 301_ IQQPQ 306_ PLIQP 311_ PPLVQ 316_ SQLPQ 321_ QQPQP 326_ PQPQQ 331_ QQGPQ 336_ PQAQP 341_ HQVQP 346_ QQQQL 351_ QNRWV 356_ APRNR 361_ GAGFN 366_ QNNGA 371_ GSENF 376_ GLGVV 381_ PVSAS 386_ PSSVE 391_ VHPVL 396_ EKLKA 401_ INNYN 406_ PKDFD 411_ WNLKN 416_ GRVFI 421_ IKSYS 426_ EDDIH 431_ RSIKY 436_ SIWCS 441_ TEHGN 446_ KRLDA 451_ AYRSL 456_ NGKGP 461_ LYLLF 466_ SVNGS 471_ GHFCG 476_ VAEMK 481_ SVVDY 486_ NAYAG 491_ VWSQD 496_ KWKGK 501_ FEVKW 506_ IFVKD 511_ VPNNQ 516_ LRHIR 521_ LENND 526_ NKPVT 531_ NSRDT 536_ QEVPL 541_ EKAKQ 546_ VLKII 551_ ATFKH 556_ TTSIF 561_ DDFAH 566_ YEKRQ 571_ EEEEA 576_MRRER
1: Specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, and regulates their stability (PubMed:28106072, PubMed:28106076, PubMed:28281539, PubMed:32492408). M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing (PubMed:22575960, PubMed:24284625, PubMed:28106072, PubMed:28281539, PubMed:32492408). Acts as a regulator of mRNA stability by promoting degradation of m6A-containing mRNAs via interaction with the CCR4-NOT complex or PAN3 (PubMed:32492408). The YTHDF paralogs (YTHDF1, YTHDF2 and YTHDF3) share m6A-containing mRNAs targets and act redundantly to mediate mRNA degradation and cellular differentiation (PubMed:28106072, PubMed:28106076, PubMed:32492408). Acts as a negative regulator of type I interferon response by down-regulating interferon-stimulated genes (ISGs) expression: acts by binding to FOXO3 mRNAs (By similarity). Binds to FOXO3 mRNAs independently of METTL3-mediated m6A modification (By similarity). Can also act as a regulator of mRNA stability in cooperation with YTHDF2 by binding to m6A-containing mRNA and promoting their degradation (PubMed:28106072). Recognizes and binds m6A-containing circular RNAs (circRNAs); circRNAs are generated through back-splicing of pre-mRNAs, a non-canonical splicing process promoted by dsRNA structures across circularizing exons (PubMed:28281539). Promotes formation of phase-separated membraneless compartments, such as P-bodies or stress granules, by undergoing liquid-liquid phase separation upon binding to mRNAs containing multiple m6A-modified residues: polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their disordered regions and thereby leading to phase separation (PubMed:31292544, PubMed:31388144, PubMed:32451507). The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated membraneless compartments, such as P-bodies, stress granules or neuronal RNA granules (PubMed:31292544). May also recognize and bind N1-methyladenosine (m1A)-containing mRNAs: inhibits trophoblast invasion by binding to m1A-methylated transcripts of IGF1R, promoting their degradation (PubMed:32194978)
2: Has some antiviral activity against HIV-1 virus: incorporated into HIV-1 particles in a nucleocapsid-dependent manner and reduces viral infectivity in the next cycle of infection (PubMed:32053707). May interfere with this early step of the viral life cycle by binding to N6-methyladenosine (m6A) modified sites on the HIV-1 RNA genome (PubMed:32053707)